{"count": 81, "results": [{"_id": "34396246", "pmid": 34396246, "pmcid": "PMC8352126", "title": "Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo", "journal": "JACC CardioOncol", "authors": ["Giugliano RP", "Gencer B", "Wiviott SD", "Park JG", "Fuchs CS", "Goessling W", "Musliner TA", "Tershakovec AM", "Blazing MA", "Califf R", "Cannon CP", "Braunwald E"], "date": "2020-09-15T00:00:00Z", "doi": "10.1016/j.jaccao.2020.07.008", "meta_date_publication": "2020 Sep", "meta_volume": "2", "meta_issue": "3", "meta_pages": "385-396", "score": 50277.402, "text_hl": "(IMPROVE-IT: Examining Outcomes in Subjects With @<m>DISEASE_Acute_Coronary_Syndrome</m> @DISEASE_MESH:D054058 @@@Acute Coronary Syndrome@@@: @CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination @CHEMICAL_MESH:D000069499 @@@Vytorin@@@ [@CHEMICAL_Ezetimibe @CHEMICAL_MESH:D000069438 @@@Ezetimibe@@@/@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@] vs @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ [P04103]; NCT00202878)", "citations": {"NLM": "Giugliano RP, Gencer B, Wiviott SD, Park JG, Fuchs CS, Goessling W, Musliner TA, Tershakovec AM, Blazing MA, Califf R, Cannon CP, Braunwald E. Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo JACC CardioOncol. 2020 Sep;2(3):385-396. PMID: 34396246", "BibTeX": "@article{34396246, title={Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo}, author={Giugliano RP and Gencer B and Wiviott SD and Park JG and Fuchs CS and Goessling W and Musliner TA and Tershakovec AM and Blazing MA and Califf R and Cannon CP and Braunwald E}, journal={JACC CardioOncol}, volume={2}, number={3}, pages={385-396}}"}}, {"_id": "37335632", "pmid": 37335632, "pmcid": "PMC10256384", "title": "Statin versus ezetimibe-statin for incident atrial fibrillation among patients with type 2 diabetes mellitus with acute coronary syndrome and acute ischemic stroke", "journal": "Medicine (Baltimore)", "authors": ["Hu WS", "Yu TS", "Lin CL"], "date": "2023-06-09T00:00:00Z", "doi": "10.1097/MD.0000000000033907", "meta_date_publication": "2023 Jun 9", "meta_volume": "102", "meta_issue": "23", "meta_pages": "e33907", "score": 50267.28, "text_hl": "We identified @SPECIES_9606 @@@patients@@@ coexisting with @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@T2DM@@@, @<m>DISEASE_Acute_Coronary_Syndrome</m> @DISEASE_MESH:D054058 @@@ACS@@@ and @DISEASE_Ischemic_Stroke @DISEASE_MESH:D000083242 @@@AIS@@@ who received @CHEMICAL_Ezetimibe @CHEMICAL_MESH:D000069438 @@@ezetimibe@@@-@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ treatment as the case group and the index date was the date of first use of the @CHEMICAL_Ezetimibe @CHEMICAL_MESH:D000069438 @@@ezetimibe@@@-@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@. ", "citations": {"NLM": "Hu WS, Yu TS, Lin CL. Statin versus ezetimibe-statin for incident atrial fibrillation among patients with type 2 diabetes mellitus with acute coronary syndrome and acute ischemic stroke Medicine (Baltimore). 2023 Jun 9;102(23):e33907. PMID: 37335632", "BibTeX": "@article{37335632, title={Statin versus ezetimibe-statin for incident atrial fibrillation among patients with type 2 diabetes mellitus with acute coronary syndrome and acute ischemic stroke}, author={Hu WS and Yu TS and Lin CL}, journal={Medicine (Baltimore)}, volume={102}, number={23}, pages={e33907}}"}}, {"_id": "36763180", "pmid": 36763180, "title": "Benefit of Combination Ezetimibe/Simvastatin Among High-Risk Populations: Lessons from the IMPROVE-IT Trial.", "journal": "Curr Atheroscler Rep", "authors": ["Oliver W", "Giugliano RP"], "date": "2023-03-01T00:00:00Z", "doi": "10.1007/s11883-023-01084-4", "meta_date_publication": "2023 Mar", "meta_volume": "25", "meta_issue": "3", "meta_pages": "85-93", "score": 50262.81, "text_hl": "PURPOSE OF REVIEW: The Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) demonstrated the clinical benefit of the combination of @CHEMICAL_Ezetimibe @CHEMICAL_MESH:D000069438 @@@ezetimibe@@@-@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ compared to placebo-@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ following @<m>DISEASE_Acute_Coronary_Syndrome</m> @DISEASE_MESH:D054058 @@@acute coronary syndrome@@@ (@<m>DISEASE_Acute_Coronary_Syndrome</m> @DISEASE_MESH:D054058 @@@ACS@@@). ", "citations": {"NLM": "Oliver W, Giugliano RP. Benefit of Combination Ezetimibe/Simvastatin Among High-Risk Populations: Lessons from the IMPROVE-IT Trial. Curr Atheroscler Rep. 2023 Mar;25(3):85-93. PMID: 36763180", "BibTeX": "@article{36763180, title={Benefit of Combination Ezetimibe/Simvastatin Among High-Risk Populations: Lessons from the IMPROVE-IT Trial.}, author={Oliver W and Giugliano RP}, journal={Curr Atheroscler Rep}, volume={25}, number={3}, pages={85-93}}"}}, {"_id": "34620406", "pmid": 34620406, "title": "Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT.", "journal": "J Am Coll Cardiol", "authors": ["Oyama K", "Giugliano RP", "Blazing MA", "Park JG", "Tershakovec AM", "Sabatine MS", "Cannon CP", "Braunwald E"], "date": "2021-10-12T00:00:00Z", "doi": "10.1016/j.jacc.2021.08.011", "meta_date_publication": "2021 Oct 12", "meta_volume": "78", "meta_issue": "15", "meta_pages": "1499-1507", "score": 50255.336, "text_hl": "(IMPROVE-IT: Examining Outcomes in Subjects With @<m>DISEASE_Acute_Coronary_Syndrome</m> @DISEASE_MESH:D054058 @@@Acute Coronary Syndrome@@@: @CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination @CHEMICAL_MESH:D000069499 @@@Vytorin@@@ [@CHEMICAL_Ezetimibe @CHEMICAL_MESH:D000069438 @@@Ezetimibe@@@/@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@] vs @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ [P04103]; NCT00202878).", "citations": {"NLM": "Oyama K, Giugliano RP, Blazing MA, Park JG, Tershakovec AM, Sabatine MS, Cannon CP, Braunwald E. Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. J Am Coll Cardiol. 2021 Oct 12;78(15):1499-1507. PMID: 34620406", "BibTeX": "@article{34620406, title={Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT.}, author={Oyama K and Giugliano RP and Blazing MA and Park JG and Tershakovec AM and Sabatine MS and Cannon CP and Braunwald E}, journal={J Am Coll Cardiol}, volume={78}, number={15}, pages={1499-1507}}"}}, {"_id": "32720602", "pmid": 32720602, "title": "Have We Learnt all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease).", "journal": "Curr Vasc Pharmacol", "authors": ["Fras Z", "Mikhailidis DP"], "date": "2021-01-01T00:00:00Z", "doi": "10.2174/1570161118999200727224946", "meta_date_publication": "2021", "meta_volume": "19", "meta_issue": "5", "meta_pages": "451-468", "score": 50249.01, "text_hl": "IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) was a randomized clinical trial (including 18,144 @SPECIES_9606 @@@patients@@@) that evaluated the efficacy of the combination of @CHEMICAL_Ezetimibe @CHEMICAL_MESH:D000069438 @@@ezetimibe@@@ with @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ vs. @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ monotherapy in @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Acute_Coronary_Syndrome</m> @DISEASE_MESH:D054058 @@@acute coronary syndrome@@@ (@<m>DISEASE_Acute_Coronary_Syndrome</m> @DISEASE_MESH:D054058 @@@ACS@@@) and moderately increased low-density lipoprotein cholesterol (LDL-C) levels (of up to 2.6-3.2 mmol/L; 100-120 mg/dL). ", "citations": {"NLM": "Fras Z, Mikhailidis DP. Have We Learnt all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease). Curr Vasc Pharmacol. 2021;19(5):451-468. PMID: 32720602", "BibTeX": "@article{32720602, title={Have We Learnt all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease).}, author={Fras Z and Mikhailidis DP}, journal={Curr Vasc Pharmacol}, volume={19}, number={5}, pages={451-468}}"}}, {"_id": "36260325", "pmid": 36260325, "title": "Association of Serial High-Sensitivity Cardiac Troponin T With Subsequent Cardiovascular Events in Patients Stabilized After Acute Coronary Syndrome: A Secondary Analysis From IMPROVE-IT.", "journal": "JAMA Cardiol", "authors": ["Patel SM", "Qamar A", "Giugliano RP", "Jarolim P", "Marston NA", "Park JG", "Blazing MA", "Cannon CP", "Braunwald E", "Morrow DA"], "date": "2022-12-01T00:00:00Z", "doi": "10.1001/jamacardio.2022.3627", "meta_date_publication": "2022 Dec 1", "meta_volume": "7", "meta_issue": "12", "meta_pages": "1199-1206", "score": 50237.957, "text_hl": "Design, Setting, and @SPECIES_9606 @@@Participants@@@: This is a secondary analysis from the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT), a randomized clinical trial of @CHEMICAL_Ezetimibe @CHEMICAL_MESH:D000069438 @@@ezetimibe@@@ vs placebo on a background of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ in 18 144 @SPECIES_9606 @@@patients@@@ hospitalized for an @<m>DISEASE_Acute_Coronary_Syndrome</m> @DISEASE_MESH:D054058 @@@ACS@@@ across 1147 sites in 39 countries. ", "citations": {"NLM": "Patel SM, Qamar A, Giugliano RP, Jarolim P, Marston NA, Park JG, Blazing MA, Cannon CP, Braunwald E, Morrow DA. Association of Serial High-Sensitivity Cardiac Troponin T With Subsequent Cardiovascular Events in Patients Stabilized After Acute Coronary Syndrome: A Secondary Analysis From IMPROVE-IT. JAMA Cardiol. 2022 Dec 1;7(12):1199-1206. PMID: 36260325", "BibTeX": "@article{36260325, title={Association of Serial High-Sensitivity Cardiac Troponin T With Subsequent Cardiovascular Events in Patients Stabilized After Acute Coronary Syndrome: A Secondary Analysis From IMPROVE-IT.}, author={Patel SM and Qamar A and Giugliano RP and Jarolim P and Marston NA and Park JG and Blazing MA and Cannon CP and Braunwald E and Morrow DA}, journal={JAMA Cardiol}, volume={7}, number={12}, pages={1199-1206}}"}}, {"_id": "31426749", "pmid": 31426749, "pmcid": "PMC6700958", "title": "Effects of ezetimibe/simvastatin 10/10 mg versus Rosuvastatin 10 mg on carotid atherosclerotic plaque inflammation", "journal": "BMC Cardiovasc Disord", "authors": ["Oh M", "Kim H", "Shin EW", "Sung C", "Kim DH", "Moon DH", "Lee CW"], "date": "2019-08-19T00:00:00Z", "doi": "10.1186/s12872-019-1184-2", "meta_date_publication": "2019 Aug 19", "meta_volume": "19", "meta_issue": "1", "meta_pages": "201", "score": 50075.13, "text_hl": "Among the 146 screened @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Acute_Coronary_Syndrome</m> @DISEASE_MESH:D054058 @@@acute coronary syndrome@@@, 96 did not fulfill the eligibility criteria for the present study, and 50 @SPECIES_9606 @@@patients@@@ were eventually randomized to either the @CHEMICAL_Ezetimibe @CHEMICAL_MESH:D000069438 @@@ezetimibe@@@/@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ group or the @CHEMICAL_Rosuvastatin_Calcium @CHEMICAL_MESH:D000068718 @@@rosuvastatin@@@ group. ", "citations": {"NLM": "Oh M, Kim H, Shin EW, Sung C, Kim DH, Moon DH, Lee CW. Effects of ezetimibe/simvastatin 10/10 mg versus Rosuvastatin 10 mg on carotid atherosclerotic plaque inflammation BMC Cardiovasc Disord. 2019 Aug 19;19(1):201. PMID: 31426749", "BibTeX": "@article{31426749, title={Effects of ezetimibe/simvastatin 10/10 mg versus Rosuvastatin 10 mg on carotid atherosclerotic plaque inflammation}, author={Oh M and Kim H and Shin EW and Sung C and Kim DH and Moon DH and Lee CW}, journal={BMC Cardiovasc Disord}, volume={19}, number={1}, pages={201}}"}}, {"_id": "25731133", "pmid": 25731133, "title": "Ezetimibe plus moderate-dose simvastatin after acute coronary syndrome: what are we IMPROVEing on?", "journal": "Am J Med", "authors": ["DiNicolantonio JJ", "Chatterjee S", "Lavie CJ", "Bangalore S", "O'Keefe JH"], "date": "2015-08-01T00:00:00Z", "doi": "10.1016/j.amjmed.2015.01.034", "meta_date_publication": "2015 Aug", "meta_volume": "128", "meta_issue": "8", "meta_pages": "914.e1-4", "score": 50069.133, "text_hl": "@CHEMICAL_Ezetimibe @CHEMICAL_MESH:D000069438 @@@Ezetimibe@@@ plus moderate-dose @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ after @<m>DISEASE_Acute_Coronary_Syndrome</m> @DISEASE_MESH:D054058 @@@acute coronary syndrome@@@: what are we IMPROVEing on?", "citations": {"NLM": "DiNicolantonio JJ, Chatterjee S, Lavie CJ, Bangalore S, O'Keefe JH. Ezetimibe plus moderate-dose simvastatin after acute coronary syndrome: what are we IMPROVEing on? Am J Med. 2015 Aug;128(8):914.e1-4. PMID: 25731133", "BibTeX": "@article{25731133, title={Ezetimibe plus moderate-dose simvastatin after acute coronary syndrome: what are we IMPROVEing on?}, author={DiNicolantonio JJ and Chatterjee S and Lavie CJ and Bangalore S and O'Keefe JH}, journal={Am J Med}, volume={128}, number={8}, pages={914.e1-4}}"}}, {"_id": "28796030", "pmid": 28796030, "pmcid": "PMC5556196", "title": "The renoprotective effects of simvastatin and atorvastatin in patients with acute coronary syndrome undergoing percutaneous coronary intervention", "journal": "Medicine (Baltimore)", "authors": ["Ma H", "Liu Y", "Xie H", "Zhang G", "Zhan H", "Liu Z", "Wang P", "Geng Q", "Guo L"], "date": "2017-08-01T00:00:00Z", "doi": "10.1097/MD.0000000000007351", "meta_date_publication": "2017 Aug", "meta_volume": "96", "meta_issue": "32", "meta_pages": "e7351", "score": 50067.73, "text_hl": "The renoprotective effects of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ and @CHEMICAL_Atorvastatin @CHEMICAL_MESH:D000069059 @@@atorvastatin@@@ in @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Acute_Coronary_Syndrome</m> @DISEASE_MESH:D054058 @@@acute coronary syndrome@@@ undergoing percutaneous coronary intervention", "citations": {"NLM": "Ma H, Liu Y, Xie H, Zhang G, Zhan H, Liu Z, Wang P, Geng Q, Guo L. The renoprotective effects of simvastatin and atorvastatin in patients with acute coronary syndrome undergoing percutaneous coronary intervention Medicine (Baltimore). 2017 Aug;96(32):e7351. PMID: 28796030", "BibTeX": "@article{28796030, title={The renoprotective effects of simvastatin and atorvastatin in patients with acute coronary syndrome undergoing percutaneous coronary intervention}, author={Ma H and Liu Y and Xie H and Zhang G and Zhan H and Liu Z and Wang P and Geng Q and Guo L}, journal={Medicine (Baltimore)}, volume={96}, number={32}, pages={e7351}}"}}, {"_id": "21558878", "pmid": 21558878, "title": "Ezetimibe combined with simvastatin compared with simvastatin alone results in a greater suppression of oxidative stress and enhanced fibrinolysis in patients after acute coronary events.", "journal": "J Cardiovasc Pharmacol", "authors": ["Undas A", "Machnik A", "Potaczek DP", "Wypasek E", "Zmudka K", "Tracz W"], "date": "2011-08-01T00:00:00Z", "doi": "10.1097/FJC.0b013e31821e8cb2", "meta_date_publication": "2011 Aug", "meta_volume": "58", "meta_issue": "2", "meta_pages": "167-72", "score": 50067.496, "text_hl": "@CHEMICAL_Ezetimibe @CHEMICAL_MESH:D000069438 @@@Ezetimibe@@@ combined with @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ compared with @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ alone results in a greater suppression of oxidative stress and enhanced fibrinolysis in @SPECIES_9606 @@@patients@@@ after @<m>DISEASE_Acute_Coronary_Syndrome</m> @DISEASE_MESH:D054058 @@@acute coronary@@@ events.", "citations": {"NLM": "Undas A, Machnik A, Potaczek DP, Wypasek E, Zmudka K, Tracz W. Ezetimibe combined with simvastatin compared with simvastatin alone results in a greater suppression of oxidative stress and enhanced fibrinolysis in patients after acute coronary events. J Cardiovasc Pharmacol. 2011 Aug;58(2):167-72. PMID: 21558878", "BibTeX": "@article{21558878, title={Ezetimibe combined with simvastatin compared with simvastatin alone results in a greater suppression of oxidative stress and enhanced fibrinolysis in patients after acute coronary events.}, author={Undas A and Machnik A and Potaczek DP and Wypasek E and Zmudka K and Tracz W}, journal={J Cardiovasc Pharmacol}, volume={58}, number={2}, pages={167-72}}"}}]}